Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

This study tests a combination of three drugs — Orelabrutinib, Zebetuzumab, and Lenalidomide — for people newly diagnosed with marginal zone lymphoma (MZL), a slow-growing type of blood cancer that affects the lymph nodes, spleen, or stomach. **You may be eligible if...** - You are 18–75 years old - You have been newly diagnosed with marginal zone lymphoma confirmed by tissue biopsy (MALT, splenic MZL, or nodal MZL) - Your cancer is CD20-positive (a protein found on the cancer cells) - You have at least one measurable area of disease - Your disease meets standard treatment criteria (symptoms, organ damage, rapid progression, or patient preference) **You may NOT be eligible if...** - You have previously received treatment for this lymphoma - You have certain active infections, poor organ function, or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.